A detective story for biomedical footprints towards new therapeutic interventions in diabetic nephropathy

Internal Medicine

Volumn 42, Issue 12, 2003, Pages 1165-1171

  Miyata, Toshio ^a   Kurokawa, Kiyoshi ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Advanced glycation end product; Anti hypertensive agent; Carbonyl stress; Oxidative stress; Protein modification; Renoprotection

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2 ISOPROPYLIDENEHYDRAZONO 4 OXO THIAZOLIDIN 5 YLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ALT 946; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR; ANTIDIABETIC AGENT; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; HYDRALAZINE; HYDRAZINE DERIVATIVE; INSULIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NIFEDIPINE; OLMESARTAN; PYRIDOXAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TEMOCAPRILAT; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; METABOLIC PARAMETERS; MOLECULAR MECHANICS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN FOOTPRINTING; PROTEIN MODIFICATION; QUANTITATIVE ANALYSIS; RAT; REVIEW;

EID: 1642504352     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.1165     Document Type: Review

References (40)

1. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993.
2. Bravi MC, Pietrangeli P, Laurenti O, et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 46: 1194-1198, 1997.
3. Jennings PE, Chirico S, Jones AF, Lunec J, Barnett AH. Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res 6: 151-154, 1987.
4. Suzuki E, Yasuda K, Takeda N, et al. Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract 18:153-158, 1992.
5. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55: 389-399, 1999.
6. Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, Baynes JW. Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 100: 839-846, 1997, 100.
7. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100: 2995-3004, 1997.
8. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264: 21597-21602, 1989.
9. e-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261: 4889-4894, 1986.
10. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12: 255-258, 1997.
11. Miyata S, Monnier VM. Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal anti-body to pyrraline. J Clin Invest 89: 1102-1112, 1992.
12. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10: 822-832, 1999.
13. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107: 853-860, 2001.
14. Requena JR, Fu MX, Ahmed MU, et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 322: 317-325, 1997.
15. Uchida K, Kanematsu M, Sakai K, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 95: 4882-4887, 1998.
16. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 98: 1283-1289, 1996.
17. Ischiropoulos H, al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 364: 279-282, 1995.
18. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61: 186-194, 2002.
19. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 232: 1629-1632, 1986.
20. Nakamura S, Makita Z, Ishikawa S, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46: 895-899, 1997.
21. Miyata T, Ueda Y, Asahi K, et al. Mechanism of the inhibitory effect of OPB-9195 [(±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 11: 1719-1725, 2000.
22. Miyata T, Ueda Y, Yamada Y, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 9: 2349-2356, 1998.
23. Miyata T, Horie K, Ueda Y, et al. Advanced glycation and lipoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 58: 425-435, 2000.
24. Akhand AA, Kato M, Suzuki H, et al. Carbonyl compounds cross-link cellular proteins and activate protein-tyrosine kinase p60c-Src. J Cell Biochem 72: 1-7, 1999.
25. Miyata T, Ishikawa S, Asahi K, et al. 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: Role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS lett 445: 202-206, 1999.
26. Taguchi T, Sugiura M, Hamada Y, Miwa I. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem Pharmacol 55: 1667-1671, 1998.
27. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 13: 2478-2487, 2002.
28. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14: 1212-1222, 2003.
29. Michaelis OE, Patrick DH, Hansen CT, Canary JJ, Werner RM, Carswell N. Insulin-independent diabetes mellitus (type II) spontaneous hypertensive/NIH corpulent rat. Am J Pathol 123: 398-400, 1986.
30. Takaya K, Ogawa Y, Hiraoka J, et al. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 14: 130-131, 1996.
31. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 60: 228-234, 2001.
32. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
33. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002.
34. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334, 1991.
35. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106: 672-678, 2000.
36. Heart outcomes prevention evaluation (HOPE) study investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000.
37. Pitt B, Poole-Wilson PA, Segal R, et al. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trail - The losartan heart failure survival study ELITE II. Lancet 355: 1582-1587, 2000.
38. Weinberg MS, Weiberg AJ, Cord R, Zappe DH. The effect of high dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J Renin Angiotensin Aldosterone System 2 (suppl 1): S196-S198, 2001.
39. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51: 3274-3282, 2002.
40. Wilkinson-Berka JL, Kelly DJ, Koerner SM, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat. Diabetes 51: 3283-3289, 2002.